FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年9月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 聯康生物科技集團有限公司(於開曼群島註冊成立之有限公司) 呈交日期: 2025年10月3日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00690 | 說明 | 聯康生物科技集團 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 500,000,000,000 | HKD | | 0.01 | HKD | | 5,000,000,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 500,000,000,000 | HKD | ...

近日，联康生物科技集团发布公告，其全资子公司北京博康健基因科技有限公司与科兴生物制药股份有 限公司签订战略合作协议，授予科兴制药在沙特阿拉伯、埃及、摩洛哥、哥伦比亚、阿根廷及墨西哥六 个国家(合作区域)独家商业化集团创新骨质疏松治疗药物博固泰®的权利。 智通财经APP获悉，香港联交所最新资料显示，9月23日，联康生物科技集团(00690)股东将股票存入香 港上海汇丰银行，存仓市值1.13亿港元，占比12.33%。 ...

香港联交所最新资料显示，9月23日，联康生物科技集团(00690)股东将股票存入香港上海汇丰银行，存 仓市值1.13亿港元，占比12.33%。 近日，联康生物科技集团发布公告，其全资子公司北京博康健基因科技有限公司与科兴生物制药股份有 限公司签订战略合作协议，授予科兴制药在沙特阿拉伯、埃及、摩洛哥、哥伦比亚、阿根廷及墨西哥六 个国家(合作区域)独家商业化集团创新骨质疏松治疗药物博固泰的权利。 ...

23 September 2025 Uni-Bio Science Group Limited (the "Company") – Notification of Publication of Interim Report 2025 ("Current Corporate Communications") The English and Chinese versions of the Company's Current Corporate Communications are now available on the Company's website at www.uni-bioscience.com and the website of The Stock Exchange of Hong Kong Limited (the "Stock Exchange") at www.hkexnews.hk respectively (the "Website Version"). The Company strongly recommends you to access the Website Version o ...

(Incorporated in the Cayman Islands with limited liability) （於開曼群島註冊成立的有限公司） （Stock Code 股份代號：0690） NOTIFICATION LETTER 通知信函 Dear Non-registered Holder(s)(Note 1) , 23 September 2025 Uni-Bio Science Group Limited (the "Company") - Notification of Publication of Interim Report 2025 ("Current Corporate Communications") The English and Chinese versions of the Company's Current Corporate Communications are available on the Company's website at www.uni-bioscience.com and the website of The Stock Exchange of Hong ...

獨立非執行董事 周啓明先生 任啓民先生 馬青山先生 審核委員會 周啓明先生 （審核委員會主席） 任啓民先生 馬青山先生 目錄 2 公司資料 4 主要財務摘要 6 管理層討論及分析 32 簡明綜合損益及其他全面收益表 34 簡明綜合財務狀況表 36 簡明綜合現金流量表 37 簡明綜合權益變動表 39 簡明綜合財務報表附註 59 其他資料 公司資料 董事會 執行董事 梁國龍先生 （主席） 陳大偉先生 （副主席） 趙志剛先生 （行政總裁） 聞亞磊博士 （首席運營官） 非執行董事 邱國榮先生 張清女士 薪酬委員會 周啓明先生 （薪酬委員會主席） 梁國龍先生 任啓民先生 馬青山先生 提名委員會 梁國龍先生 （提名委員會主席） 張清女士 周啓明先生 馬青山先生 任啓民先生 公司秘書 何詠欣女士 （ACG, HKACG (PE)） 授權代表 梁國龍先生 陳大偉先生 核數師 香港立信德豪會計師事務所有限公司 執業會計師 註冊辦事處 Cricket Square Hutchins Drive P.O. Box 2681 Grand Cayman, KY1-1111 Cayman Islands 總辦事處兼香港主要營業地點 香港 ...

Group 1 - The core point of the news is the strategic partnership between Link Health Biotechnology Group and Sinovac Biotech, granting Sinovac exclusive commercialization rights for the osteoporosis treatment drug Bogu Tai® in six countries [1][2] - Bogu Tai® is a new generation osteoporosis treatment that promotes bone formation and increases bone density, specifically designed for postmenopausal women at high risk of fractures [1] - The target market for this partnership includes over 10 million osteoporosis patients, with a market size of nearly $1.5 billion, providing significant opportunities for Bogu Tai® in these underserved markets [1] Group 2 - Since its launch in China in March 2024, Bogu Tai® has achieved remarkable success, with revenue growth of 248.9% year-on-year in the first half of 2025 [1] - The partnership is seen as a key milestone in Sinovac's global expansion strategy, reinforcing its position in the osteoporosis treatment market and delivering long-term value to shareholders [2]

Group 1 - The core point of the news is the strategic partnership between Link Health Biotechnology Group and Sinovac Biotech, granting Sinovac exclusive commercialization rights for the osteoporosis treatment drug, Bogu Tai, in six countries [1][2] - Bogu Tai is a new generation osteoporosis treatment that promotes bone formation and increases bone density, specifically designed for postmenopausal women at high risk of fractures [1] - The target market for this partnership includes over 10 million osteoporosis patients, with a market size of nearly $1.5 billion, providing significant opportunities for Bogu Tai in these underserved markets [1] Group 2 - Since its launch in China in March 2024, Bogu Tai has achieved remarkable success, with revenue growth of 248.9% year-on-year in the first half of 2025 [1] - The collaboration is seen as a key milestone in Sinovac's global expansion strategy, reinforcing its position in the osteoporosis treatment market and delivering long-term value to shareholders [2]

Group 1 - The core point of the news is the strategic partnership between Beijing Bokan Gene Technology Co., Ltd. and Sinovac Biotech Ltd. for the exclusive commercialization of the osteoporosis treatment drug Bogu Tai® in six countries, which presents significant market opportunities [1] - Bogu Tai® is a new generation osteoporosis treatment that promotes bone formation and increases bone density, specifically designed for postmenopausal women at high risk of fractures, addressing unmet medical needs in the market [1] - The target market for this partnership includes over 10 million osteoporosis patients with a market size of nearly $1.5 billion, indicating a substantial opportunity for growth [1] Group 2 - Sinovac Biotech is a leading innovative multinational biopharmaceutical company with operations in multiple countries and regions, which has achieved market access and sales in dozens of global markets [2] - The board of Sinovac Biotech views this collaboration as a key milestone in its global expansion strategy, reinforcing its position in the osteoporosis treatment market and providing long-term value for shareholders [2] - Since its launch in China in March 2024, Bogu Tai® has seen significant success, with revenue growth of 248.9% year-on-year in the first half of 2025, indicating strong market demand and performance [1]

Core Viewpoint - 联康生物科技集团 has entered into a strategic cooperation agreement with 科兴制药 for the exclusive commercialization of its innovative osteoporosis treatment drug, 博固泰, in six countries [1] Group 1: Company Overview - 联康生物科技集团's subsidiary, 北京博康健基因科技有限公司, will collaborate with 科兴制药 to expand the market for 博固泰 in Saudi Arabia, Egypt, Morocco, Colombia, Argentina, and Mexico [1] - 博固泰 is recognized as China's first approved pre-filled teriparatide injection, designed to enhance patient comfort and adherence through a fine needle and precise delivery system [1] Group 2: Product Details - 博固泰 is a next-generation osteoporosis treatment that promotes bone formation and increases bone density, addressing significant unmet medical needs for postmenopausal women at high risk of fractures [1]